Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Labcorp Holdings ( (LH) ) has issued an update.
Labcorp Holdings Inc. announced it will release its financial results for the second quarter of 2025 on July 24, 2025, before the market opens. The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the results, with the earnings press release and financial information available on the Labcorp Investor Relations website. A replay of the webcast will be accessible until July 11, 2026.
The most recent analyst rating on (LH) stock is a Buy with a $274.00 price target. To see the full list of analyst forecasts on Labcorp Holdings stock, see the LH Stock Forecast page.
Spark’s Take on LH Stock
According to Spark, TipRanks’ AI Analyst, LH is a Outperform.
Labcorp Holdings demonstrates a solid financial foundation and positive earnings outlook, supported by strategic initiatives and product innovation. While technical indicators and valuation suggest moderate risk, strong earnings growth and corporate governance measures enhance its overall attractiveness.
To see Spark’s full report on LH stock, click here.
More about Labcorp Holdings
Labcorp Holdings Inc. is a global leader in innovative and comprehensive laboratory services, providing diagnostics and drug development capabilities to support doctors, hospitals, pharmaceutical companies, researchers, and patients. With nearly 70,000 employees, Labcorp operates in approximately 100 countries and played a role in the approval of over 75% of new drugs and therapeutic products by the FDA in 2024, performing over 700 million tests annually worldwide.
Average Trading Volume: 804,253
Technical Sentiment Signal: Buy
Current Market Cap: $21.65B
Learn more about LH stock on TipRanks’ Stock Analysis page.